OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial
Manish A. Shah, Kohei Shitara, Jaffer A. Ajani, et al.
Nature Medicine (2023) Vol. 29, Iss. 8, pp. 2133-2141
Open Access | Times Cited: 243
Manish A. Shah, Kohei Shitara, Jaffer A. Ajani, et al.
Nature Medicine (2023) Vol. 29, Iss. 8, pp. 2133-2141
Open Access | Times Cited: 243
Showing 1-25 of 243 citing articles:
Exploring treatment options in cancer: Tumor treatment strategies
Beilei Liu, Hongyu Zhou, Licheng Tan, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 186
Beilei Liu, Hongyu Zhou, Licheng Tan, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 186
Antibodies to watch in 2024
Silvia Crescioli, Hélène Kaplon, Alicia M. Chenoweth, et al.
mAbs (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 87
Silvia Crescioli, Hélène Kaplon, Alicia M. Chenoweth, et al.
mAbs (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 87
Cancer therapy with antibodies
Suman Paul, Maximilian F. Konig, Drew M. Pardoll, et al.
Nature reviews. Cancer (2024) Vol. 24, Iss. 6, pp. 399-426
Closed Access | Times Cited: 55
Suman Paul, Maximilian F. Konig, Drew M. Pardoll, et al.
Nature reviews. Cancer (2024) Vol. 24, Iss. 6, pp. 399-426
Closed Access | Times Cited: 55
Claudin 18.2 as a novel therapeutic target
Izuma Nakayama, Changsong Qi, Yang Chen, et al.
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 5, pp. 354-369
Closed Access | Times Cited: 49
Izuma Nakayama, Changsong Qi, Yang Chen, et al.
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 5, pp. 354-369
Closed Access | Times Cited: 49
Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer
Julien Dilly, Megan T. Hoffman, Laleh Abbassi, et al.
Cancer Discovery (2024) Vol. 14, Iss. 11, pp. 2135-2161
Closed Access | Times Cited: 41
Julien Dilly, Megan T. Hoffman, Laleh Abbassi, et al.
Cancer Discovery (2024) Vol. 14, Iss. 11, pp. 2135-2161
Closed Access | Times Cited: 41
Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results
Changsong Qi, Chang Liu, Jifang Gong, et al.
Nature Medicine (2024) Vol. 30, Iss. 8, pp. 2224-2234
Closed Access | Times Cited: 38
Changsong Qi, Chang Liu, Jifang Gong, et al.
Nature Medicine (2024) Vol. 30, Iss. 8, pp. 2224-2234
Closed Access | Times Cited: 38
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with gastric cancer
Kohei Shitara, Tania Fleitas, Hisato Kawakami, et al.
ESMO Open (2024) Vol. 9, Iss. 2, pp. 102226-102226
Open Access | Times Cited: 26
Kohei Shitara, Tania Fleitas, Hisato Kawakami, et al.
ESMO Open (2024) Vol. 9, Iss. 2, pp. 102226-102226
Open Access | Times Cited: 26
Recent developments in immunotherapy for gastrointestinal tract cancers
Xiaoyi Chong, Yelizhati Madeti, Jieyuan Cai, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 21
Xiaoyi Chong, Yelizhati Madeti, Jieyuan Cai, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 21
Enhancing antitumor efficacy of CLDN18.2-directed antibody-drug conjugates through autophagy inhibition in gastric cancer
Wenjing Xue, Caili Xu, Kaiqi Zhang, et al.
Cell Death Discovery (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 21
Wenjing Xue, Caili Xu, Kaiqi Zhang, et al.
Cell Death Discovery (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 21
Oesophageal cancer
Hong Yang, Feng Wang, Christopher L. Hallemeier, et al.
The Lancet (2024) Vol. 404, Iss. 10466, pp. 1991-2005
Closed Access | Times Cited: 20
Hong Yang, Feng Wang, Christopher L. Hallemeier, et al.
The Lancet (2024) Vol. 404, Iss. 10466, pp. 1991-2005
Closed Access | Times Cited: 20
Zolbetuximab in Gastric or Gastroesophageal Junction Adenocarcinoma
Kohei Shitara, Manish A. Shah, Florian Lordick, et al.
New England Journal of Medicine (2024) Vol. 391, Iss. 12, pp. 1159-1162
Closed Access | Times Cited: 17
Kohei Shitara, Manish A. Shah, Florian Lordick, et al.
New England Journal of Medicine (2024) Vol. 391, Iss. 12, pp. 1159-1162
Closed Access | Times Cited: 17
Consensus, debate, and prospective on pancreatic cancer treatments
Junke Wang, Jie Yang, Amol Narang, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 17
Junke Wang, Jie Yang, Amol Narang, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 17
Korean Practice Guidelines for Gastric Cancer 2024: An Evidence-based, Multidisciplinary Approach (Update of 2022 Guideline)
In‐Ho Kim, Seung Joo Kang, Wonyoung Choi, et al.
Journal of the Korean Gastric Cancer Association (2025) Vol. 25, Iss. 1, pp. 5-5
Closed Access | Times Cited: 5
In‐Ho Kim, Seung Joo Kang, Wonyoung Choi, et al.
Journal of the Korean Gastric Cancer Association (2025) Vol. 25, Iss. 1, pp. 5-5
Closed Access | Times Cited: 5
Claudin 18.2-targeting antibody–drug conjugate CMG901 in patients with advanced gastric or gastro-oesophageal junction cancer (KYM901): a multicentre, open-label, single-arm, phase 1 trial
Dan-Yun Ruan, Furong Liu, Xiao-Li Wei, et al.
The Lancet Oncology (2025)
Closed Access | Times Cited: 4
Dan-Yun Ruan, Furong Liu, Xiao-Li Wei, et al.
The Lancet Oncology (2025)
Closed Access | Times Cited: 4
A Comprehensive and Comparative Review of Global Gastric Cancer Treatment Guidelines: 2024 Update
Sang Soo Eom, Keun Won Ryu, Hye Sook Han, et al.
Journal of the Korean Gastric Cancer Association (2025) Vol. 25, Iss. 1, pp. 153-153
Open Access | Times Cited: 3
Sang Soo Eom, Keun Won Ryu, Hye Sook Han, et al.
Journal of the Korean Gastric Cancer Association (2025) Vol. 25, Iss. 1, pp. 153-153
Open Access | Times Cited: 3
Digestive cancers: mechanisms, therapeutics and management
Tianzuo Zhan, Johannes Betge, Nadine Schulte, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access | Times Cited: 2
Tianzuo Zhan, Johannes Betge, Nadine Schulte, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access | Times Cited: 2
Novel drugs approved by the EMA, the FDA and the MHRA in 2024: A year in review
Stavros Topouzis, Andreas Papapetropoulos, S P H Alexander, et al.
British Journal of Pharmacology (2025)
Open Access | Times Cited: 2
Stavros Topouzis, Andreas Papapetropoulos, S P H Alexander, et al.
British Journal of Pharmacology (2025)
Open Access | Times Cited: 2
Clinicopathologic features and prognostic value of claudin 18.2 overexpression in patients with resectable gastric cancer
Hyung‐Don Kim, Eugene Choi, Jinho Shin, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 25
Hyung‐Don Kim, Eugene Choi, Jinho Shin, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 25
Treatment of gastric adenocarcinoma: A rapidly evolving landscape
Julien Taı̈eb, Jaafar Bennouna, Frédérique Penault-Llorca, et al.
European Journal of Cancer (2023) Vol. 195, pp. 113370-113370
Open Access | Times Cited: 23
Julien Taı̈eb, Jaafar Bennouna, Frédérique Penault-Llorca, et al.
European Journal of Cancer (2023) Vol. 195, pp. 113370-113370
Open Access | Times Cited: 23
Zolbetuximab for Claudin18.2-positive gastric or gastroesophageal junction cancer
Yohei Kubota, Kohei Shitara
Therapeutic Advances in Medical Oncology (2024) Vol. 16
Open Access | Times Cited: 13
Yohei Kubota, Kohei Shitara
Therapeutic Advances in Medical Oncology (2024) Vol. 16
Open Access | Times Cited: 13
Heterogeneity of claudin 18.2 expression in metastatic gastric cancer
Eugene Choi, Jinho Shin, Min‐Hee Ryu, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 12
Eugene Choi, Jinho Shin, Min‐Hee Ryu, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 12
Metastatic gastric cancer target lesion complete response with Claudin18.2-CAR T cells
Gregory P. Botta, Joseph Chao, H. Ma, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 2, pp. e007927-e007927
Open Access | Times Cited: 11
Gregory P. Botta, Joseph Chao, H. Ma, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 2, pp. e007927-e007927
Open Access | Times Cited: 11
Claudin 18.2 as a New Biomarker in Gastric Cancer—What Should We Know?
Maria Cecília Mathias-Machado, Victor Hugo Fonseca de Jesus, Alexandre A. Jácome, et al.
Cancers (2024) Vol. 16, Iss. 3, pp. 679-679
Open Access | Times Cited: 11
Maria Cecília Mathias-Machado, Victor Hugo Fonseca de Jesus, Alexandre A. Jácome, et al.
Cancers (2024) Vol. 16, Iss. 3, pp. 679-679
Open Access | Times Cited: 11
Adjuvant treatment for locally advanced gastric cancer: an Asian perspective
Hyung‐Don Kim, Min‐Hee Ryu, Yoon‐Koo Kang
Gastric Cancer (2024) Vol. 27, Iss. 3, pp. 439-450
Closed Access | Times Cited: 11
Hyung‐Don Kim, Min‐Hee Ryu, Yoon‐Koo Kang
Gastric Cancer (2024) Vol. 27, Iss. 3, pp. 439-450
Closed Access | Times Cited: 11
Global prevalence of claudin 18 isoform 2 in tumors of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma
Kohei Shitara, Rui‐Hua Xu, Jaffer A. Ajani, et al.
Gastric Cancer (2024) Vol. 27, Iss. 5, pp. 1058-1068
Open Access | Times Cited: 11
Kohei Shitara, Rui‐Hua Xu, Jaffer A. Ajani, et al.
Gastric Cancer (2024) Vol. 27, Iss. 5, pp. 1058-1068
Open Access | Times Cited: 11
